Dyno Therapeutics, based in Boston, MA, is revolutionizing the field of gene therapy by harnessing the power of artificial intelligence (AI). By combining AI algorithms with cutting-edge genetic engineering techniques, Dyno Therapeutics is unlocking new possibilities for the treatment of genetic diseases.
One of the key challenges in gene therapy is the delivery of therapeutic genes to the target cells in the body. Dyno Therapeutics is addressing this challenge by using AI to design optimized viral vectors that can efficiently deliver genes to specific cell types.
For example, Dyno Therapeutics has developed an AI platform called CapsidMap, which uses machine learning algorithms to analyze the structure of viral capsids - the protein shells that encapsulate viral DNA. By understanding the relationship between capsid structure and viral transduction efficiency, Dyno Therapeutics can predict which viral vectors are most likely to successfully deliver genes to target cells.
This AI-driven approach has the potential to significantly enhance the effectiveness of gene therapies. By optimizing viral vectors, Dyno Therapeutics can increase the precision and efficiency of gene delivery, leading to better therapeutic outcomes for patients.
Furthermore, Dyno Therapeutics is also leveraging AI to accelerate the discovery of novel gene therapies. Through their AI platform, they can rapidly screen and analyze vast libraries of genetic sequences to identify potential therapeutic targets and optimize the design of therapeutic genes.
- Dyno Therapeutics website. Available at: https://www.dynotx.com/
- Deverman BE, et al. (2018). Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 36(11):1059-1070.
- Patil AS, et al. (2019). CapsidMap: a next-generation sequencing-based method to identify functionally relevant regions in viral capsid proteins. Hum Gene Ther. 30(1):111-122.
How to Contact Us:
Address: 343 Arsenal St suite 101, Watertown, MA 02472, USA
Call us: (617) 417-8259